Navigation Links
Jury Verdict Against Novartis Pharmaceuticals For Retaliating Against Drug Sales Rep Who Took Maternity Leave
Date:3/9/2010

WASHINGTON, March 9 /PRNewswire/ -- On March 5, 2010, a jury in the United States District Court for the District of Columbia rendered a verdict in favor of pharmaceutical sales representative Mary Kate Breeden, awarding $289,669 against Novartis Pharmaceuticals Corporation on her claim of retaliation for taking maternity leave covered by the Family and Medical Leave Act (FMLA).  Under the FMLA's liquidated damages provision, this amount is automatically doubled to $579,338.  The District Court has yet to decide the amount front pay, attorney fees, and costs to award.

Mary Kate Breeden worked as a pharmaceutical sales representative for Novartis for over seven (7) years.  After announcing that she was pregnant, Novartis cut her sales territory in half leaving her with fewer and smaller accounts.  When she objected to the change, her supervisor said it was temporary and that she would be made "whole."  Upon returning from maternity leave, Breeden was informed that the change was permanent.  Novartis reorganized the sales territories again, at which time they consolidated Breeden's territory with another and eliminated her position.  Novartis claimed that an outside consulting firm coordinated the original realignment and did not take Breeden's FMLA leave into account.  However, Breeden's maternity leave was mentioned in a PowerPoint presentation that the consulting firm prepared about the realignment.  

The jury found that Novartis retaliated against Ms. Breeden by cutting her sales territory when she announced that she was going to take leave and when Novartis refused to make her "whole" after she returned to work from FMLA leave, ultimately damaging her career and leading to her termination.  Adam Augustine Carter, a Principal at The Employment Law Group® law firm (www.employmentlawgroup.com), a premier employment law firm based in D.C., stated, "The jury of 12 believed Ms. Breeden and disbelieved the executives of Novartis in arriving at this verdict.  She was committed to her job, but her employer questioned her commitment.  No employee should have to choose between having a family or keeping their job, and this jury verdict will help teach that lesson to all employers covered by the FMLA."  

The Employment Law Group specializes in representing employees in whistleblower, wrongful termination, and discrimination cases.  To contact them regarding questions or comments, call R. Scott Oswald or Adam Augustine Carter at 202-331-3911.

SOURCE The Employment Law Group, P.C.

Back to top

RELATED LINKS
http://www.employmentlawgroup.net

'/>"/>

SOURCE The Employment Law Group, P.C.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Maryland Woman Thankful for Wyeth Verdicts
2. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
3. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
4. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
5. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
6. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
7. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
8. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
9. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
10. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
11. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology:
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):